All In Biotech

Drug Trial Radar · NCT03846310

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

77

Actual

Start

Apr 1, 2019

Primary completion

Nov 18, 2024

Study completion Nov 18, 2024

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Feb 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

Conditions

  • Non Small Cell Lung Cancer Metastatic
  • Non Small Cell Lung Cancer
  • Nonsquamous Nonsmall Cell Neoplasm of Lung
  • Sensitizing EGFR Gene Mutation

Interventions

  • EtrumadenantDrug

    Etrumadenant is an A2aR and A2bR antagonist

  • ZimberelimabDrug

    Zimberelimab is a fully human anti-PD-1 monoclonal antibody

  • CarboplatinDrug

    Carboplatin administered as part of standard chemotherapy regimen

  • PemetrexedDrug

    Pemetrexed administered as part of standard chemotherapy regimen

  • PembrolizumabDrug

    Pembrolizumab is a humanized anti-PD-1 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with Adverse EventsTime frame: From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)
  2. Percentage of participants who experience a Dose Limiting ToxicityTime frame: From first study treatment administration through Day 21

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Arizona Cancer Research Center (ACRC)

    Tucson, Arizona

  • SCRI Florida Cancer Specialists - South

    Fort Myers, Florida

  • SCRI Florida Cancer Specialists - North

    Tavares, Florida

  • SCRI Tennessee Oncology - Nashville

    Nashville, Tennessee

  • USO Texas Oncology - Dallas (Baylor Charles A. Sammons Cancer Center)

    Dallas, Texas

  • USO Virginia Cancer Specialist

    Fairfax, Virginia

  • USO Virginia Oncology Associates

    Norfolk, Virginia

  • Medical Oncology Associates/Summit Cancer Center

    Spokane, Washington

  • National University Hospital

    Singapore, Singapore

  • National Cancer Centre Singapore

    Singapore, Singapore

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

  • Bundang CHA Medical Center

    Seongnam-si, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Centre

    Seoul, South Korea

  • Seoul St. Mary's Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Suwon, South Korea

  • The Catholic University of Korea St. Vincent Hospital

    Suwon, Gyeonggi-do, South Korea

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Taipei Medical University - Shuang Ho Hospital

    New Taipei City, Taiwan

  • Chi Mei Hospital, Liouying

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Tri Service General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.